A Clinical Study of Iparomlimab and Tuvonralimab Combined With SOX Following Heterogeneous Radiotherapy as First-line Treatment for Unresectable Locally Advanced or Metastatic HER2-negative Gastric or Gastroesophageal Junction Adenocarcinoma

Clinical trial NCT07502027 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07502027
Sponsor: Huazhong University of Science and Technology
Status: NOT_YET_RECRUITING
Phase: Phase 4
Study type: INTERVENTIONAL

Gastric Cancer (Diagnosis)Gastric Cancer (GC)Gastroesophageal Junction Adenocarcinoma

Start date: 2026-06-01
Primary completion: 2028-03-31
Enrollment: 55

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.